Clinical trials: Respiratory Allergy
Asthma
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the…
- Trial name
- NCT01196039
- Testing
- MEMP1972A
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Moderate Asthma
A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma
The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.
- Trial name
- NCT00974675
- Testing
- CAT-354 1mg/kg, CAT-354 5 mg/kg, CAT-354 10mg/kg
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- MedImmune LLC
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System
Collection of quantitative data to demonstrate the accuracy (bias) and precision (repeatability) of the Apieron INSIGHT(tm) eNO Breath System as compared to the FDA cleared NIOX eNO Breath System when testing is performed by…
- Trial name
- NCT00739531
- Testing
- Exhaled nitric oxide (eNO)
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Apieron
Asthma
Arnuity® Ellipta® Drug Use Investigation
The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice.
- Trial name
- NCT03184480
- Testing
- Arnuity Ellipta
- Where
- 2 sites in Japan
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Phleum Pratense DT/DRF
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense…
- Trial name
- NCT01682070
- Testing
- SUBLIVAC FIX phleum prat.
- Where
- 23 sites in Germany, Poland
- Volunteers
- 266 people
- Sponsor
- HAL Allergy
Asthma
Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.
The Kata® App is a digital therapy assistant for patients with asthma who need to inhale their therapy. Kata features inhalation trainers that shows patients in a simple and understandable way how to improve their inhalation…
- Trial name
- NCT06178341
- Testing
- Kata Inhalations-App
- Where
- 13 sites in Germany
- Volunteers
- 146 people
- Sponsor
- VisionHealth GmbH
Bronchial Asthma
Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of Inhalation aerosol PA9159, to establish maximum tolerated dose in…
- Trial name
- NCT06916273
- Testing
- PA9159 Inhalation aerosol, 60 μg one day treatment, PA9159 Inhalation aerosol, 120 μg one day treatment, PA9159 Inhalation aerosol, 240 μg one day treatment
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.
Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients
This study is designed to investigate the safety and tolerability of multiple doses of QAX576 in controlled or partially controlled asthma patients.
- Trial name
- NCT00940160
- Testing
- QAX576
- Where
- 3 sites in Russia, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils.
- Trial name
- NCT03287310
- Testing
- GSK3511294, Salbutamol/albuterol
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Healthy Subjects
Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
- Trial name
- NCT03384290
- Testing
- PRS-060
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Asthma and Rhinitis
Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958.
- Trial name
- NCT02446613
- Testing
- Pollen allergen extract
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily.
- Trial name
- NCT00163345
- Testing
- Ciclesonide
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial
Probiotic Administration and Perennial Allergic Rhinitis
The purpose of this study is to evaluate the efficacy of a probiotic strain in improving the quality of life in adult subjects suffering from perennial allergic rhinit.
- Trial name
- NCT01779895
- Testing
- Lactobacillus paracasei probiotic strain
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Société des Produits Nestlé (SPN)
Asthma, Respiratory Symptoms
Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)
To evaluate the level of control of Asthma (GINA : controlled, partially controlled, not controlled) of asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low)…
- Trial name
- SAISON (NCT00882128)
- Where
- 1,051 sites in France
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Asthma
Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01554319
- Testing
- SB010
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Perennial Allergic Rhinitis
Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.
The loratadine-pseudoephedrine combination has proven to be more effective than the use of these individual components. This prospective, randomized, double-blind and paralel study, in which patients with perennial allergic…
- Trial name
- NCT01228630
- Testing
- Cloratadd-D, Allegra-D
- Where
- Brazil
- Volunteers
- 156 people
- Sponsor
- Azidus Brasil
Rhinitis, Allergic, Perennial
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis
The aim of this trial is to evaluate the clinical efficacy and safety of Epinastine 10 mg + Pseudoephedrine 120 mg slow release (SR) administered twice a day, compared to Epinastine 10 mg alone administered twice daily.
- Trial name
- NCT02182518
- Testing
- Epinastine, Pseudoephedrine
- Volunteers
- 101 people
- Sponsor
- Boehringer Ingelheim
Rhino Sinusitis
Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans
Rhinitis is a type of upper respiratory infection with a common nasal pathology especially in Southeast Asia, which is characterized by the presence of one or more of the following symptoms: itchy nose, sneezing, runny nose, and…
- Trial name
- NCT05984004
- Testing
- 0.9% NaCl isotonic saline solution, Bacillus subtilis DSM32444, inactivated
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huro Biotech Joint Stock Company
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.